Literature DB >> 17630556

Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.

Elena Chiappini1, Luisa Galli, Pier-Angelo Tovo, Clara Gabiano, Catiuscia Lisi, Guido Castelli Gattinara, Susanna Esposito, Alessandra Viganò, Carlo Giaquinto, Raffaella Rosso, Alfredo Guarino, Maurizio de Martino.   

Abstract

BACKGROUND: The introduction of HAART has decreased mortality and progression to AIDS in perinatally HIV-1-infected children, but information on modification of the rate of specific clinical events is limited.
METHOD: An observational population study on changes in HIV-1-related morbidity was conducted on 1402 perinatally HIV-1-infected children enrolled in the Italian Register for HIV Infection in Children and prospectively followed in the pre-HAART (1985-1995) and post-HAART periods (1996-2000, and 2001-2005). Of this group, 773 children (55.1%) were followed from birth. Median observation time was 8.58 years (interquartile range, 3.71-13.72).
RESULTS: Overall, 666 (47.5%) children developed AIDS and 420 (29.9%) died. Improved survival over time was evidenced at Kaplan-Meier analysis (P < 0.0001). Poisson regression analysis indicated that Centers for Disease Control and Prevention class B and C clinical event rates and most of the HIV-1-related organ complication rates significantly decreased starting from 1996-2000. Significant reductions in rates of cancer and opportunistic infections were evidenced after 2000. Nevertheless, opportunistic infections still occurred at high rates (6.09/100 person-years) in 2001-2005, with high rate of bacterial infections (3.55/100 person-years), particularly pneumonia (1.66/100 person-years), in this period. CD4 cell percentage was > 15% in 58.5% children with pneumonia.
CONCLUSIONS: Progressive reductions of both mortality and rates of class B and C clinical events, including organ complications, were evidenced in the HAART era. Nevertheless, severe bacterial infections, particularly pneumonia, still occurred at considerable high rates, even in the absence of a severe CD4 cell depletion.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630556     DOI: 10.1097/QAD.0b013e32823ecf5b

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  23 in total

1.  Mortality trends in the US Perinatal AIDS Collaborative Transmission Study (1986-2004).

Authors:  Bill G Kapogiannis; Minn M Soe; Steven R Nesheim; Elaine J Abrams; Rosalind J Carter; John Farley; Paul Palumbo; Linda J Koenig; Marc Bulterys
Journal:  Clin Infect Dis       Date:  2011-11       Impact factor: 9.079

2.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

3.  Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007.

Authors:  Alberto N Ramos; Luiza H Matida; Norman Hearst; Jorg Heukelbach
Journal:  AIDS Res Ther       Date:  2011-07-18       Impact factor: 2.250

Review 4.  Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Authors:  Elizabeth Peacock-Villada; Barbra A Richardson; Grace C John-Stewart
Journal:  Pediatrics       Date:  2011-01-24       Impact factor: 7.124

5.  Opportunistic and other infections in HIV-infected children in Latin America compared to a similar cohort in the United States.

Authors:  Jorge O Alarcón; Laura Freimanis-Hance; Margot Krauss; Mary F Reyes; Claudete Aparecida Araújo Cardoso; Marisa M Mussi-Pinhata; Edmundo Cardoso; Rohan Hazra
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-19       Impact factor: 2.205

6.  Timing of antiretroviral therapy initiation and its impact on disease progression in perinatal human immunodeficiency virus-1 infection.

Authors:  Amy S Sturt; Meira S Halpern; Barbara Sullivan; Yvonne A Maldonado
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

Review 7.  Pulmonary infections in HIV-positive children.

Authors:  Reena George; Savvas Andronikou; Salomine Theron; Jaco du Plessis; Murray Hayes; Pierre Goussard; Ayanda Mapukata; Robert Gie
Journal:  Pediatr Radiol       Date:  2009-03-14

8.  Temporal trends in mucocutaneous findings among human immunodeficiency virus 1-infected children in a population-based cohort.

Authors:  Amy S Sturt; Andrew Anglemyer; David R Berk; Yvonne A Maldonado
Journal:  Pediatr Dermatol       Date:  2012-11-07       Impact factor: 1.588

9.  Five-year follow-up of children with perinatal HIV-1 infection receiving early highly active antiretroviral therapy.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Catiuscia Lisi; Stefania Bernardi; Alessandra Viganò; Alfredo Guarino; Carlo Giaquinto; Susanna Esposito; Raffaele Badolato; Cesare Di Bari; Raffaella Rosso; Orazio Genovese; Massimo Masi; Antonio Mazza; Maurizio de Martino
Journal:  BMC Infect Dis       Date:  2009-08-26       Impact factor: 3.090

10.  Bridging the gap between adult and paediatric outcomes in HIV-1 vertically infected children: a single-centre comparison with adult data.

Authors:  F Monpoux; P Puglièse; F Berthier; J Cottalorda; C Pradier
Journal:  Acta Paediatr       Date:  2009-08-04       Impact factor: 2.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.